Carboprost tromethamine is a synthetic form of the hormone prostaglandin F2α, which has been used in medical practice for over four decades now. It is commonly used to induce labor, control postpartum hemorrhage and terminate pregnancy, among other uses. This article will discuss carboprost tromethamine in detail, with an emphasis on the various uses and dosages for medical professionals. In addition, it will provide information on safety concerns and potential side effects that healthcare professionals should be aware of when administering this medication to their patients.
Carboprost tromethamine is a synthetic prostaglandin analogue used to induce labor and control postpartum hemorrhage. It is sold under the brand names Hemabate and Methergine. Carboprost tromethamine has a similar structure to natural prostaglandins, which are hormones that play an important role in regulating many bodily functions, including labor and delivery. When given as an injection, carboprost tromethamine works by stimulating contractions of the uterus and increasing the production of oxytocin, a hormone that helps control bleeding after childbirth. Carboprost tromethamine is typically only used when other methods of induction or control of postpartum hemorrhage have failed.
Carboprost tromethamine is indicated for the medical termination of pregnancy through 63 days gestational age. It can also be used to control postpartum hemorrhage when uterine contractions are inadequate. Common side effects of carboprost tromethamine include nausea, vomiting, diarrhea, abdominal pain and fever.
Carboprost tromethamine (Hemabate) is a prostaglandin F2-alpha analogue used to treat postpartum hemorrhage (PPH) due to uterine atony. It is administered as an intramuscular injection. The recommended dose of carboprost tromethamine for the treatment of PPH is 0.25 mg/kg administered intramuscularly every 15 minutes for two doses, followed by 0.5 mg/kg every 30 minutes for four doses, and then 1 mg/kg every 60 minutes as needed. The maximum recommended dose is 30 mg per day. For the prevention of PPH, the recommended dose of carboprost tromethamine is 0.5 mg/kg administered intramuscularly immediately after delivery of the placenta.
Carboprost tromethamine is a medication used to help induce labor or to control bleeding after childbirth or abortion. It is a synthetic version of the hormone prostaglandin F2α. Carboprost tromethamine should only be used under the supervision of a medical professional. Carboprost tromethamine should only be used under the supervision of a medical professional. It is not intended for use by pregnant women without medical supervision. This medication can cause uterine contractions. This medication can also cause side effects such as nausea, vomiting, diarrhea, abdominal pain and headache.
Carboprost tromethamine (Hemabate) is a synthetic prostaglandin used to induce labor or terminate pregnancy. It can also be used to control postpartum bleeding. Carboprost tromethamine works by causing the uterus to contract. Common side effects of carboprost tromethamine include nausea, vomiting, diarrhea, headache and dizziness. This medication may also cause uterine rupture and other serious side effects in pregnant women.
Drug interactions may occur with carboprost tromethamine. The most common drug interactions include: Nonsteroidal anti-inflammatory drugs (NSAIDs), Anticoagulants (blood thinners), Aspirin, Barbiturates, Corticosteroids, Diuretics (water pills), estrogens, lithium
Carboprost Tromethamine is an important medication used to treat several medical conditions. As a medical professional, it is essential that you understand the uses, dosages and other aspects of using this drug correctly. We hope this article has provided all of the necessary information for safely administering Carboprost Tromethamine so that you can ensure your patients are receiving the best care possible.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.
2.
Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness
3.
Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer
4.
According to a study, taking part in a clinical trial for cancer may not actually increase survival.
5.
A new blood test greatly increases the ability to detect cancer.
1.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
2.
Unraveling the Mysteries of Hematocrit: How It Impacts Your Health
3.
The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers
4.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
5.
Surprising Symptoms of Prostate Cancer: What You Need to Know
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation